ClinicalTrials.gg
RecruitingNCT07007910Updated Jun 6, 2025

Phase I Study of HSK46575 in Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 interventional study of HSK46575 in m CRPC, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Recruiting at 1 site in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-06.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Dec 2024, registered May 2025).
  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Study summary

This is a phase I, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK(pharmacokinetics) and PD(pharmacodynamics) of HSK46575 when given orally in patients with metastatic castration-resistant prostate cancer.

Read the detailed description

The study will contain two phases: Phase Ia is dose escalation phase and Phase Ib is dose expansion phase.

Phase Ia will contain two part: Dose Escalation Part and Extension Part. Dose Escalation Part based on the "3+3" design for dose escalation and safety evaluation requirements. Patient cohorts at selected doses may be extended to further investigate the tolerability, PK and PD of HSK46575. The number of patients to be enrolled will be up to 10 subjects in each Extension Part cohort. Approximately 30 subjects will be enrolled in Phase Ia.

Phase Ib no less than 60 subjects will be enrolled in each expansion cohort.

02

Conditions studied

  • m CRPC
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male, aged ≥18 years;
  2. (Eastern Cooperative Oncology Group) 0-1, expected survival of ≥ 3 months;
  3. Histology or cytology confirmed adenocarcinoma of the prostate;
  4. Radiological evidence of bone or soft tissue lesions;
  5. Ongoing medical castration or previous surgical castration;
  6. Testosterone at castration level during screening;
  7. Prior to screening, subjects with evidence of disease progression while receiving ADT (androgen deprivation therapy);
  8. Had progressed on at least one novel endocrine therapy, and had progressed on at least one taxane-based chemotherapy (or those who are intolerant or refuse chemotherapy);
  9. The functional level of organs must meet the requirements.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with known to the active ingredient or of HSK46575 Tablets;
  2. Subjects who have received any antitumor therapy within 4 weeks (or 5 half-lives, whichever is shorter) prior to the first dose; or treatment with nitrosoureas, bicalutamide, or nilutamide within 6 weeks (or 5 half-lives, whichever is shorter) prior to the first dose;
  3. Subjects whose toxicity from prior anticancer therapy remains > Grade 1 before the first dose;
  4. Subjects who have used strong or moderate inhibitors or inducers, CYP2C9 sensitive substrates, and OCT2 or MATE1 substrates within 14 days or 5 half-lives prior to the first dose of the drug, whichever is longer;
  5. Subjects who have undergone Grade 3-4 surgery;
  6. Subjects who plan to receive any other antitumor therapy during the study ;
  7. Subjects with active to central nervous system;
  8. Subjects with serious bone damage caused by prostate cancer bone metastasis as assessed by the investigators;
  9. Within 6 months before the first dose, subjects had concurrent pituitary or adrenal dysfunction;
  10. Subjects with uncontrolled hypertension;
  11. Subjects with central nervous system disorders such as epilepsy and multiple sclerosis;
  12. Subjects with active cardiac disease within 6 months prior to the first dose, or a history of arterial or venous thromboembolism;
  13. Subjects with a prolongation to >470 ms during the screening period calculated by the Fridericia formula;
  14. Subjects with a history of other ;
  15. Subjects with a history of immunodeficiency;
  16. Subjects with active , , or syphilis infection;
  17. Subjects who have participated in other clinical studies within 4 weeks before the first dose;
  18. Other conditions.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Phase Ia (Dose Escalation Part): HSK46575

    Phase 1a (Dose Escalation Part): dose escalation of HSK46575 at various dose levels

    Drug: HSK46575

  • Experimental
    Phase Ia (Extension Part): HSK46575

    Phase 1a (Part B): dose extention of HSK46575 at certain dose levels

    Drug: HSK46575

  • Experimental
    Phase Ib: HSK46575

    Phase 1b: dose expansion for HSK46575 at dose of RP2D(Recommended Phase II Dose)

    Drug: HSK46575

Interventions

  • DrugHSK46575

    co-administered with glucocorticoid and fludrocortisone, orally daily

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD)

    Highest dose level at which under 33% of patients in a cohort experience DLT(dose limiting toxicity)

    Time frame: Within first 28 days of treatment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 22, 2025
First posted
Jun 6, 2025
StartActual
Dec 18, 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jun 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07007910
Responsible party
Sponsor
First posted
Jun 6, 2025
Start date
Dec 18, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jun 6, 2025

Study contacts

Yunfen Li
Contact
liyunfen@haisco.com
18108214952

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion